Ultrasonographic evaluation of focal hepatic lesions: comparison of pulse inversion harmonic, tissue harmonic, and conventional imaging techniques.

2000 ◽  
Vol 19 (5) ◽  
pp. 293-299 ◽  
Author(s):  
H J Jang ◽  
H K Lim ◽  
W J Lee ◽  
S H Kim ◽  
K A Kim ◽  
...  
Keyword(s):  
Imaging Techniques ◽  
Conventional Imaging ◽  
Pulse Inversion ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions

scholarly journals Focal Hepatic Lesions: Contrast-Enhancement Patterns at Pulse-Inversion Harmonic US using a Microbubble Contrast Agent

2003 ◽  
Vol 4 (4) ◽  
pp. 224 ◽  
Author(s):  
Eun-A Kim ◽  
Kwon-Ha Yoon ◽  
Young Hwan Lee ◽  
Hye Won Kim ◽  
Seon Kwan Juhng ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Contrast Enhancement ◽  
Microbubble Contrast Agent ◽  
Pulse Inversion ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions

Focal hepatic lesions: Differential diagnosis with MRI

1993 ◽  
Vol 29 (4) ◽  
pp. 747
Author(s):  
Jong Sool Ihm ◽  
Kwi Ae Park ◽  
Woo Hyun Ahn ◽  
Bong Gi Kim ◽  
Han Yong Choi
Keyword(s):  
Differential Diagnosis ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions

scholarly journals Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors

2021 ◽  
Author(s):  
Fred Saad ◽  
Martin Bögemann ◽  
Kazuhiro Suzuki ◽  
Neal Shore
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Second Generation ◽  
Imaging Techniques ◽  
Specific Antigen ◽  
Conventional Imaging ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Therapeutic Decisions ◽  
Consensus Statements

Abstract Background Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging. Patients with nmCRPC progress to metastatic disease and are at risk of developing cancer-related symptoms and morbidity, eventually dying of their disease. While patients with nmCRPC are generally asymptomatic from their disease, they are often older and have chronic comorbidities that require long-term concomitant medication. Therefore, careful consideration of the benefit–risk profile of potential treatments is required. Methods In this review, we will discuss the rationale for early treatment of patients with nmCRPC to delay metastatic progression and prolong survival, as well as the factors influencing this treatment decision. We will focus on oral pharmacotherapy with the second-generation androgen receptor inhibitors, apalutamide, enzalutamide, and darolutamide, and the importance of balancing the clinical benefit they offer with potential adverse events and the consequential impact on quality of life, physical capacity, and cognitive function. Results and conclusions While the definition of nmCRPC is well established, the advent of next-generation imaging techniques capable of detecting hitherto undetectable oligometastatic disease in patients with nmCRPC has fostered debate on the criteria that inform the management of these patients. However, despite these developments, published consensus statements have maintained that the absence of metastases on conventional imaging suffices to guide such therapeutic decisions. In addition, the prolonged metastasis-free survival and recently reported positive overall survival outcomes of the three second-generation androgen receptor inhibitors have provided further evidence for the early use of these agents in patients with nmCRPC in order to delay metastases and prolong survival. Here, we discuss the benefit–risk profiles of apalutamide, enzalutamide, and darolutamide based on the data available from their pivotal clinical trials in patients with nmCRPC.

MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.

1993 ◽  
Vol 161 (6) ◽  
pp. 1191-1198 ◽  
Author(s):  
T C Winter ◽  
P C Freeny ◽  
H V Nghiem ◽  
L A Mack ◽  
R M Patten ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Mr Imaging ◽  
Superparamagnetic Iron Oxide ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions

Sparing of Fatty Infiltration Around Focal Hepatic Lesions in Patients with Hepatic Steatosis: Sonographic Appearance with CT and MRI Correlation

2008 ◽  
Vol 190 (4) ◽  
pp. 1018-1027 ◽  
Author(s):  
Kyoung Won Kim ◽  
Min Ju Kim ◽  
Seung Soo Lee ◽  
Hyoung Jung Kim ◽  
Yong Moon Shin ◽  
...  
Keyword(s):  
Hepatic Steatosis ◽  
Fatty Infiltration ◽  
Sonographic Appearance ◽  
Focal Hepatic Lesions ◽  
Hepatic Lesions ◽  
Ct And Mri

Prediction of Recurrence after HCC Resection

1994 ◽  
Vol 35 (4) ◽  
pp. 329-334 ◽  
Author(s):  
M. Yamamoto ◽  
Y. Iimuro ◽  
M. Mogaki ◽  
K. Kachi ◽  
H. Fujii ◽  
...  
Keyword(s):  
Imaging Techniques ◽  
Tumor Vasculature ◽  
The Other ◽  
High Recurrence Rate ◽  
Small Hepatocellular Carcinoma ◽  
Conventional Imaging ◽  
Cumulative Survival ◽  
Preoperative Ct ◽  
Small Hcc ◽  
Better Than

In trying to clarify the high recurrence rate after removal of small hepatocellular carcinoma (HCC), we assessed the postoperative evolution of minute hepatic Lipiodol deposits which had been diagnosed as artifacts on the preoperative Lipiodol-CT. Of 27 patients with solitary HCC less than 5 cm in diameter, 14 had such Lipiodol deposits in the preoperative CT and 9 of them (64%) developed recurrent tumors. On the other hand, 6 of the 13 patients without deposits (46%) suffered recurrence, but in 5 of these 6 patients the HCC was metachronous multicentric. The cumulative survival rate of the non-deposit group was better than that of the deposit group (p < 0.1). The present study suggested that, even in patients with small HCC, minute concomitant tumors invisible by conventional imaging techniques may exist at the time of surgery. Some of these lesions without sufficient tumor vasculature showing a hypervascular blush on angiography appear to retain small, vague Lipiodol deposits.

scholarly journals Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer

2021 ◽  
Vol 22 (5) ◽  
pp. 2757
Author(s):  
Braden Miller ◽  
Hunter Chalfant ◽  
Alexandra Thomas ◽  
Elizabeth Wellberg ◽  
Christina Henson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Imaging Techniques ◽  
Growth Factor Receptor ◽  
Breast Cancer Diagnosis ◽  
Screening Mammography ◽  
Imaging Modalities ◽  
Conventional Imaging ◽  
Obese Women ◽  
Detection Rates ◽  
Therapeutic Decision Making

Obesity, diabetes, and inflammation increase the risk of breast cancer, the most common malignancy in women. One of the mainstays of breast cancer treatment and improving outcomes is early detection through imaging-based screening. There may be a role for individualized imaging strategies for patients with certain co-morbidities. Herein, we review the literature regarding the accuracy of conventional imaging modalities in obese and diabetic women, the potential role of anti-inflammatory agents to improve detection, and the novel molecular imaging techniques that may have a role for breast cancer screening in these patients. We demonstrate that with conventional imaging modalities, increased sensitivity often comes with a loss of specificity, resulting in unnecessary biopsies and overtreatment. Obese women have body size limitations that impair image quality, and diabetes increases the risk for dense breast tis-sue. Increased density is known to obscure the diagnosis of cancer on routine screening mammography. Novel molecu-lar imaging agents with targets such as estrogen receptor, human epidermal growth factor receptor 2 (HER2), pyrimi-dine analogues, and ligand-targeted receptor probes, among others, have potential to reduce false positive results. They can also improve detection rates with increased resolution and inform therapeutic decision making. These emerg-ing imaging techniques promise to improve breast cancer diagnosis in obese patients with diabetes who have dense breasts, but more work is needed to validate their clinical application.

Sign in / Sign up

Export Citation Format

Share Document